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Introduction
Skeletal fragility is increased in acromegaly, regardless 
of the bone density [1, 2]. Growth hormone (GH) excess 
is associated with increased bone turnover, deteriora-
tion of bone microarchitecture, and increased risk of 
vertebral fractures [3]. Besides the classic acromega-
ly-related risk factors [gonadal status, the presence of 
diabetes mellitus (DM), vitamin D deficiency, or over-
treatment [1]], additional alterations provoked by GH 
excess, such as body composition (BC) [4], adipokines 
[5], and fibroblast growth factor 23 (FGF23)/a-Klotho 
axis modifications [6], may also impact bone. The altered 
BC in acromegaly — increased lean mass (LM) and 
reduced fat mass (FM), but with ectopic intermuscular 
or trunk deposition — is GH mediated [4], directly or 
via chronic inflammation [7]. Leptin usually reflects the 
amount of adipose tissue, and blunted leptin levels are 
restored after successful surgery of acromegaly [8]. Both 
DM and cardiovascular disease (CVD) (frequent com-
plications of acromegaly) are associated with low levels 
of adiponectin and higher resistinaemia — negatively 
correlated with BMD in the general population [7, 9]. 
Data approaching the BC-adipokines-BMD relationship 
in acromegaly are, however, scarce [10, 11].
The FGF23/a-Klotho system negatively regulates 
phosphate and vitamin D metabolism, having an overall 
detrimental impact upon bone metabolism [12]. a-Klot-
ho was proposed as a marker for acromegaly activity 
because the higher levels encountered in active states 
dropped after treatment, but the determinant mecha-
nism remains to be elucidated [13]. To our knowledge, 
the impact of FGF23/a-Klotho on bone has not yet been 
evaluated in the acromegalic population.
We aimed to evaluate the particularities of the 
FGF23/a-Klotho axis and adipokine spectrum in rela-
tion to BC, and their influence upon bone density and 
turnover, in active acromegaly.
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Abstract 
Introduction: Body composition (BC) and adipokines share bone active properties and display an altered profile in acromegaly. The 
fibroblast growth factor 23 (FGF23)/a-Klotho system, also involved in bone metabolism, is upregulated in growth hormone (GH) excess 
states. Hence, we aimed to investigate their impact on bone in active acromegaly, compared to controls.
Material and methods: BC, bone mineral density (BMD) (via dual X-ray absorptiometry), serum adipokines (leptin, adiponectin, resistin), 
parathyroid hormone (PTH), FGF23, a-Klotho, and osteocalcin were assessed in a cross-sectional study enrolling 35 patients with active 
acromegaly (Acro), compared to 35 sex, age, and body mass index (BMI) one-to-one matched healthy controls (CTL). 
Results: The Acro group had higher bone density scores (p< 0.05), lower visceral fat depots (p = 0.011), and lower serum leptin (p < 0.001) 
but elevated adiponectin (p < 0.001) and resistin (p = 0.001) concentrations when compared to the CTL group. a-Klotho was not related 
to the GH/IGF1 axis in the Acro group. Resistin was higher in both diabetic and non-diabetic Acro compared to CTL (p < 0.05). Age and 
BC were the main independent BMD predictors in regression analysis in both groups, while IGF1 was a positive predictor of osteocalcin 
levels in the Acro (b= 0.48, p = 0.006). The correlations between adipokines, the FGF23/a-Klotho system, and bone parameters, respec-
tively, were lost after adjusting for age and BC.
Conclusions: Age and BC were the main independent BMD predictors in the acromegalic patients with active disease, while IGF1 was 
independently associated with serum osteocalcin concentrations. The role of a-Klotho in evaluating acromegaly and the associated oste-
opathy in the long-term appears to be limited. Our study is among the first to report significant serum resistin changes in patients with 
active acromegaly, opening new insights in the GH-mediated insulin resistance. The GH-resistin relationship merits further investigations. 
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mologated technicians, according to standard protocol. Low bone 
mass was defined as T-score < –1 SD at the level of the lumbar 
spine or hip for postmenopausal women and men above 50 years 
of age, and Z-score < –2 SD for premenopausal women and men 
under 50 years of age [15]. 
BC parameters (total FM, trunk FM, lower limbs FM, total LM) were 
also determined by whole-body DXA scan. Trunk-to-leg fat ratio 
was calculated as trunk FM (g)/lower limbs FM (g). 
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS 
version 20.0 for Windows, IBM SPSS Inc.). Data are expressed as 
mean ± standard error of the mean (SEM).  Normal distribution 
of data was verified using the Shapiro-Wilk test. Between-group 
and subgroup differences were assessed by [1] Student’s paired 
t-test (for normally distributed data) or the non-parametric Mann-
Whitney U test (for skewed data) for 2 variables and [2] ANOVA for 
3 or more variables. Pearson correlation (for normally distributed 
data) or Spearman rank correlation (for skewed data) was used 
to evaluate any given relationships between the assessed param-
eters. Significant correlations were further introduced in multiple 
regression analysis to determine independent predictors of bone 
parameters in the Acro and CTL groups, respectively. The level of 
significance was established according to a p-value < 0.05.
Results
The general characteristics of the 35 patients with active 
acromegaly (10 newly diagnosed and 25 long-standing 
Acro with a mean time elapsed from initial diagnosis 
of 132.77 ± 25.1 months) are presented in Table 1. At 
the time of observation, 25 were hypogonadal, 18 
were diabetic, and 22 had evidence of CVD (arterial 
hypertension, cardiac hypertrophy, or heart failure). 
All had normal functioning adrenal axis (mean serum 
cortisol = 10.26 ± 0.74 µg/dL; 2 patients were under 
glucocorticoid substitutive treatment), normal free 
T4 levels (mean serum free T4 = 1.11 ± 0.03 ng/dL; 
13 patients were under levothyroxine replacement 
therapy), normal serum calcium (9.7 ± 0.08 mg/dL), and 
phosphate (4.05 ± 0.1) and were rather obese (Tab. 1). 
Seventeen Acro group members had low bone mass 
(all of them also associated hypogonadism; 2 had prior 
history of fragility fractures), while 18 exhibited DXA 
values in the normal range. Five patients were under 
vitamin D3 supplementation.  Osteocalcin levels were 
increased (Tab. 1; reference range: 9–42 ng/mL). 
Acro had higher lumbar spine and femoral neck 
Z-scores, but a lower trunk-to-leg fat ratio compared to 
CTL, respectively (Tab. 1). Serum adipokines, but not 
FGF23 and PTH, also varied significantly between the 
2 groups (Tab. 1). 
Correlations
Acro
Significant correlations in the Acro group between age, 
BC, serum parameters and bone density and osteocal-
cin, respectively, are depicted in Table 2. IGF1, BMI, LM, 
and trunk-to-leg fat ratio were all positively correlated 
Material and methods
Study design
We performed a cross sectional, case-control study, enrolling 35 
patients with active acromegaly (Acro; after selecting the 127 ac-
romegalic patients who attended our Endocrinology Department 
for diagnostic or follow-up between April 2019 and February 2020, 
according to the criteria described below) and 35 age-, sex-, and 
body mass index (BMI)-matched, apparently healthy controls (CTL; 
general population volunteers referred by the general practitioner 
to our outpatient department for a health check-up in the same 
period of time, who met the criteria below and agreed to take part 
in the study). One-to-one individual matching was used to avoid 
gender, age, and BMI as confounders. 
Patients with active acromegaly (regardless of the disease-related 
comorbidities or therapy type, gender, gonadal status, being at 
first evaluation or at follow-up), between 20 and 80 years old were 
included in the Acro group. According to the criteria of the cur-
rent guidelines of the Endocrine Society [14] and according to our 
national protocol, respectively, active disease was defined as [1] 
insulin-like growth factor 1 (IGF1) levels above normal range for 
age and [2] failure of GH to suppress to less than 1 ng/mL during 
a 75 mg oral glucose tolerance test or 24 h GH mean value ≥ 2.5 
ng/mL in Acro with DM.
Exclusion criteria in the Acro group were represented by preg-
nancy, bone active therapy (other than vitamin D supplements), 
confirmed or suspected secondary causes of osteoporosis other 
than acromegaly related — hypogonadism and DM (e.g. primary 
hyperparathyroidism, thyrotoxicosis, hypercortisolism, major 
bone trauma, chronic kidney disease, inflammatory bowel disease, 
congenital bone disease, anorexia nervosa, malignancy, sarcoidosis, 
antioestrogen/antiandrogen therapy), and suspected or confirmed 
multiple endocrine neoplasia. In order to minimize the additional 
factors affecting bone metabolism, DM patients treated with thia-
zolidinediones or insulin were also excluded. 
All-cause secondary osteoporosis, the use of bone active drugs 
other than vitamin D supplements, the presence of DM, CVD, and 
pregnancy were also exclusion criteria in the CTL group.
Medical history was recorded, and physical examination (including 
anthropometric measurements) was performed for both groups. 
A fasting morning blood draw of 20 mL for serum determinations 
(serum aliquots were stored at –80°C until analysis) and dual 
X-ray absorptiometry (DXA) for BMD and BC assessment were 
performed, respectively.  
Hypogonadism was defined as [1] menopause — more than 
12 months since natural cessation of menstrual cycles or [2] gonado-
tropin deficiency due to the evolution of the disease.
The study adhered to the Declaration of Helsinki. The institutional 
ethics committee approved the protocol (20.03.2019), and all pa-
tients gave written informed consent before entering the study. 
Measurements
Body mass index was calculated as weight (kg)/[height (m)]2. Serum 
levels of leptin, adiponectin, resistin, FGF23, a-Klotho, IGF1, GH, 
and osteocalcin were quantified using commercially available ELISA 
Research kits (Elabscience Biotechnology, USA). Serum parathyroid 
hormone (PTH) was quantified by electrochemiluminescence 
(ECLIA), using commercial kits (Advia Centaur Intact PTH Assay, 
Siemens Healthcare Diagnostics Inc., USA). Free T4, cortisol, oestra-
diol (in women), testosterone (in men), follicle-stimulating hormone 
(FSH), and luteinizing hormone (LH) were routinely measured in 
the Acro group via ECLIA (Immulite 2000 Immunoassay System, 
Siemens). Serum concentrations of calcium, phosphate, and glucose 
were determined by colorimetry (Cobas 6000 analyser, Roche). 
HbA1c was assessed via the ion-exchange high-performance liquid 
chromatography (HPLC) method. 
BMD at the lumbar spine (the mean BMD value for L1-L4 lumbar 
vertebrae), femoral neck, 1/3 radius, and whole-body levels were 
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Table 1. General characteristics of the study participants
Parameter Acro (n = 35) CTL (n = 35) p-value
Age [y] 55.2 ± 2.33 54.14 ± 2.52 0.76
Men:Women 12:23 12:23 –
Menopause (n/total women) 18/23 18/23 –
Newly diagnosed/long-standing disease 10/25 –
Active disease time [mo]* 90.32 ± 20.44 – –
BMI [kg/m2] 31.63 ± 0.98 31.44 ± 0.89 0.88
Total FM [kg] 31.17 ± 2.01 32.05 ± 1.76 0.74
FM (%) 34.94 ± 1.4 36.04 ± 1.26 0.56
Total LM [kg] 54.61 ± 2.26 54.12 ± 2.19 0.88
LM (%) 62.46 ± 1.33 61.43 ± 1.2 0.57
Trunk-to-leg fat ratio 1.22 ± 0.04 1.42 ± 0.06 0.011
Lumbar BMD [g/cm2] 1.022 ± 0.033 0.923 ± 0.03 0.022
Lumbar Z-score 0.66 ± 0.22 -0.19 ± 0.15 0.002
Femoral neck BMD [g/cm2] 0.836 ± 0.042 0.814 ± 0.026 0.66
Femoral neck Z-score 0.98 ± 0.16 0.47 ± 0.16 0.03
Total hip BMD [g/cm2] 0.991 ± 0.029 0.952 ± 0.028 0.33
Total hip Z-score 0.85 ± 0.18 0.55 ± 0.15 0.2
1/3 radius BMD [g/cm2] 0.669 ± 0.021 0.688 ± 0.019 0.51
1/3 radius Z-score 0.31 ± 0.17 0.41 ± 0.15 0.66
Whole-body BMD [g/cm2] 1.089 ± 0.021 1.061 ± 0.025 0.39
IGF-1 [ng/mL] 
(mean for age)
437.54 ± 30.19 
(234.46 ± 7.27) – –
Basal GH [ng/mL] 7.45 ± 1.67 – –
Mean GH/24 h [ng/mL] (n = 18) 5.06 ± 1.59 – –
GH at glucose suppression test [ng/mL] (n = 17) 10.18 ± 2.89 – –
Glycaemia [mg/dL] 113.88 ± 6.28 84.15 ± 2.2 < 0.001
Osteocalcin [ng/mL] 58.46 ± 9.73 – –
Leptin [ng/mL] 14.03 ± 1.99 51.23 ± 0.89 < 0.001
Adiponectin [ug/mL] 35.98 ± 1.51 14.18 ± 4.03 < 0.001
Resistin [ng/mL] 18.91 ± 3.18 6.59 ± 0.66 0.001
PTH [pg/mL] 42.46 ± 4.57 48.26 ± 3.6 0.32
FGF23 [pg/mL] 81.75 ± 10.66 75.51 ± 3.12 0.58
Klotho [ng/mL] 9.15 ± 1.74 – –
Hypogonadism (n/total) 25/35 18/35 –
Low/normal bone mass 17/18 20/15 –
Fractures (n/total) 2/35 0/35 –
Diabetes mellitus (n/total) 18/35 0/35 –
HbA1c in DM patients (%) 7.04 ± 0.26 – –
CVD (n/total) 22/35 – –
Surgery (n) 14 – –
SST analogues (n) 18 – –
Pegvisomant (n) 7 – –
Radiotherapy (n) 10 – –
Dopamine agonists (n) 14 – –
*in long-standing patients; Data are expressed as mean ± standard error of the mean; ADPN — adiponectin; BMD — bone mineral density; BMI — body mass index; 
CTL — control group; CVD — cardiovascular disease; DM — diabetes mellitus; FGF23 — fibroblast growth factor 23; FM — fat mass; FN — femoral neck;  
GH — growth hormone; HbA1c — glycated haemoglobin; IGF-1 — insulin-like growth factor-1; LM — lean mass; mo — months; PTH — parathormone; 
SST — somatostatin; WB — whole-body; y — years
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with BMD, while age, PTH, adiponectin, and resistin 
were negatively correlated with bone density at various 
sites. IGF1 and a-Klotho were positively correlated with 
osteocalcin (Tab. 2). 
Basal GH was inversely correlated with leptin 
(r = –0.4, p = 0.031) and FM (r = –0.58, p = 0.001). 
IGF1 was not correlated with BC parameters or with 
BMI (data not shown). Likewise, we did not find any 
significant correlations between basal GH, IGF1, and the 
FGF23/a-Klotho axis in the whole group, nor when ana-
lysed separately (newly diagnosed and long-standing 
Acro)(data not shown).
CTL
Similarly to the Acro group, BMI, LM, and trunk-to-leg 
fat ratio were positively correlated with BMD, while 
age was negatively related to bone density in the CTL 
group. FGF23 was also negatively correlated with BMD 
in the CTL group. Contrary to the Acro patients, no 
significant correlations were found between adipo-
kines and bone parameters or between PTH and BMD, 
respectively (Table 3). 
Multiple regression analysis
Significant correlations were further introduced in 
unadjusted (Model 1) and gender-adjusted (Model 2) 
multiple regression analysis, with BMD at various sites 
and osteocalcin as the dependent variables, respectively 
(Table 4 — only significant predictors are shown). 
BC (LM and trunk-to-leg fat ratio — positive) and 
age (negative) were the main independent BMD pre-
dictors in both groups in unadjusted models (Model 1, 
Tab. 4); PTH was also negatively associated with femoral 
neck BMD in the Acro group. The influence of LM was 
lost in CTL, while the independent BMD predictors 
remained essentially unchanged in the Acro group after 
adjusting for gender (Model 2, Tab. 4). 
Multiple regression analysis was performed to as-
sess any independent effects of basal GH and FM upon 
serum leptin concentrations, respectively. FM, but not 
Table 2. Correlations between age, body composition, serum parameters, bone density, and osteocalcin, respectively, 






BMD WB BMD OCN Leptin ADPN Resistin











BMI – – 0.36  p = 0.041 – – –
0.76 
p < 0.001 – –
Total FM – – – – – – 0.79  p < 0.001 – –






p < 0.001 – –
–0.55  
p = 0.003 –
Trunk–to–leg 






p = 0.004 – – – –
Leptin – – – – – – 1 – –
Resistin –0.46  p = 0.015 – – – – – – – 1
ADPN – – –0.54  p = 0.003 – – – – 1 –
FGF23 – – – – – – – – –
Klotho – – – – – 0.52 p = 0.003 – – –
PTH – –0.54 p = 0.002
–0.55 
p = 0.03 – – – –
0.42  
p = 0.031 –
IGF1 0.35 p = 0.048 –
0.39 
p = 0.024 – –
0.51  
0.004 – – –
Basal GH – – – – – – –0.4  p = 0.031 – –
Glycaemia – – – – – – – – 0.5  p = 0.007
ADPN — adiponectin; BMD — bone mineral density; BMI — body mass index; FGF23 — fibroblast growth factor 23; FM — fat mass; FN — femoral neck;  
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Table 3. Correlations between age, body composition, serum parameters, and bone density, respectively, in the CTL group 
(only significant correlations are shown)
Lumbar BMD FN BMD Total Hip BMD
1/3 radius 
BMD WB BMD Leptin ADPN Resistin








p < 0.001 – – –
BMI – – 0.37  p = 0.03 – –
0.48  
p = 0.018 – –
Total FM – – – – – 0.58  p = 0.003 – –






p < 0.001 – –
–0.41 
p = 0.048 –
Trunk-to-leg 






p = 0.012 – – –
Leptin – – – – – 1 – –
Resistin – – – – – – 0.48  p = 0.018 1
ADPN – 1






p = 0.025 – – – –
PTH – – – – – – – –
ADPN — adiponectin; BMD — bone mineral density; BMI — body mass index; CTL — control group; FGF23 — fibroblast growth factor 23; FM — fat mass;  
FN — femoral neck; LM — lean mass; PTH — parathormone; WB — whole-body









1 Lumbar BMD – – – – R
2 = 0.56
p < 0.001 Age –0.48 0.004










p < 0.001 LM 0.53 0.001
3 Total hip BMD – – – – R = 0.63 p < 0.001 LM 0.53 0.008
4 1/3 radius BMD R
2 = 0.545

































1 Lumbar BMD – – – – R
2 = 0.58
p < 0.001 Age –0.5 0.003








0.001 – – – –
3 Total hip BMD R
2 = 0.82
p = 0.001 PTH –0.36 0.023 – – – –
4 1/3 radius BMD R
2 = 0.65
p < 0.001 Age –0.36 0.019
R2 = 0.82
p < 0.001
Age –0.4 0.001 





















p = 0.007 IGF1 0.48 0.006 NA NA NA NA
Model 2 = Model 1 adjusted for gender; Acro — acromegaly group; BMD — bone mineral density; CTL — control group; FN — femoral neck; LM — lean mass;  
NA — not assessed; PTH — parathormone; WB — whole-body
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basal GH, remained an independent predictor of serum 
leptin levels after adjusting for BMI (b = 0.61, p = 0.016).
Subgroup analysis in Acro
Initial diagnosis (n = 10) vs. long-standing Acro 
(n = 25)
While age, BMI, BMD, BC, serum adipokines, osteocal-
cin, glycaemia, and FGF23 were similar between the 2 
subgroups (data not shown), the newly diagnosed Acro 
patients had significantly higher serum IGF1 concentra-
tions (587.18 ± 75.47 vs. 377.68 ± 20.76 ng/mL, p = 0.023) 
and higher, although non-significantly, a-Klotho levels 
(11.57 ± 3.59 vs. 8.27 ± 2.01 ng/mL, p = 0.41) compared 
to their long-standing counterparts.
Hypogonadism and low bone mass
Hypogonadal Acro patients had significantly lower total 
hip (p = 0.002), 1/3 radius (p = 0.004), and whole-body 
(p = 0.003) BMD compared to eugonadal Acro patients, 
respectively. IGF1, leptin, resistin, PTH, FGF23, and 
a-Klotho did not differ significantly between eugonadal 
Acro patients with normal bone mass (n = 10), hypogo-
nadal Acro patients with normal bone mass (n = 8), and 
hypogonadal Acro patients with low bone mass (n = 17) 
(data not shown). However, age, adiponectin, and LM 
varied significantly between the 3 subgroups (Fig. 1).  
Diabetes mellitus
Bone density, BMI, BC, age, IGF1, basal GH, leptin, 
adiponectin, FGF23, and a-Klotho did not differ sig-
nificantly according to the presence (n = 18) or absence 
(n = 17) of DM (data not shown). Non-diabetic Acro 
patients tended to have lower resistin concentrations 
compared to diabetic Acro patients (15.9 ± 4.26 ng/mL 
vs. 21.48 ± 4.69 ng/mL, p = 0.4) but still exhibited sig-
nificantly higher serum resistin values when compared 
to the CTL group (15. 9 ± 4.26 vs. 6.59 ± 0.66, p = 0.048, 
Fig. 2). 
Cardiovascular disease
Insulin-like growth factor 1, basal GH, adipokines, 
a-Klotho, and FGF23 serum concentrations did not 
differ significantly according to the presence (n = 22) 
or absence (n = 13) of CVD (data not shown). 
Discussion
Body composition (LM and trunk-to-leg fat ratio), 
PTH, and age were the main BMD predictors in obese 
acromegalic patients with active disease in the current 
study, while IGF1 was a positive predictor of serum 
osteocalcin levels. Acromegalic patients exhibited a dif-
ferent distribution of fat mass and a corresponding 
dysregulation of the adipokine profile when compared 
to the general population, but no independent impact 
of the adipokines upon bone density and metabolism 
Figure 1. Comparison of age (A), total lean mass (B), and serum adiponectin levels (C) between eugonadal Acro patients with normal 
bone mass (n = 10) versus hypogonadal Acro patients with normal bone mass (n = 8) versus hypogonadal Acro patients with low bone 
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Figure 2. Serum resistin levels in diabetic patients with 
acromegaly (Acro) vs. non-diabetic Acro patients versus the control 
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was observed. Our study is among the first to report 
significantly higher resistin concentrations in both dia-
betic and non-diabetic acromegalic patients compared 
to CTL. a-Klotho was not related to the GH/IGF1 axis in 
our study, suggesting a limited role (if any) of a-Klotho 
in the follow-up of acromegalic patients with active 
disease. The current study is the first to investigate the 
bone impact of the FGF23/ a-Klotho axis in patients 
with active acromegaly.
Acromegalic osteopathy is characterized by in-
creased bone turnover, increased cortical porosity — de-
spite the specific increased cortical thickness — due to 
high remodelling, and also reduced trabecular bone 
volume — closely related to gonadal function [3, 11]. 
Lumbar BMD was significantly higher in Acro 
compared to age-, sex-, and BMI-matched CTL in our 
study. Although acromegalic patients often share de-
generative changes and vertebral deformities due to 
chronic GH exposure leading to an overestimation of 
lumbar spine BMD [16]; we also found higher femoral 
neck Z-scores. The anabolic effects of GH prevail upon 
the cortical bone, while DXA cannot assess the variable 
distribution of cortical and trabecular bone, thus pos-
sibly explaining increased BMD in some skeletal sites 
[17]. Acro patients also had elevated serum osteocalcin 
concentrations — closely related to the IGF1 level — re-
vealing an accelerated bone turnover, and thus confirm-
ing previously reported data [17]. Gonadal function is 
a main BMD determinant in acromegaly as well [17]. 
Age, bone mass and gonadal function are strongly 
inter-related in all populations [18]. Indeed, we reported 
lower BMD in the hypogonadal Acro patients, and age 
proved to be one of the main BMD predictors in both 
the Acro and CTL groups in our study. In agreement 
with other studies reporting a critical role for PTH in 
bone metabolism and health of the hip [19, 20], we also 
found a negative association between PTH and hip 
BMD in the Acro group. 
Body composition was the other main BMD pre-
dictor in both Acro and CTL subjects, besides age and 
PTH. The GH-mediated lipolysis, whole-body protein 
synthesis and water retention cause lean tissue increase 
and fat loss in acromegaly [7, 21]. LM is considered to 
increase bone mass through mechanical stress [22]. 
Direct data assessing the bone impact of BC changes 
in acromegalic patients are, however, scarce and lack-
ing a control group [11]. We found that [1] obese Acro 
patients with active disease had similar LM to their 
matched reference population, but higher bone mass, 
[2] the relationship between IGF1 and BMD is lost after 
adjusting for BC, but IGF1 is independently associ-
ated with bone turnover, and [3] that LM positively 
predicted BMD in the Acro group, after adjusting for 
gender. Thus, LM seems to play a greater role in BMD 
regulation in acromegaly, while IGF1 specifically im-
pacts bone turnover. 
A reduction in visceral fat in active acromegaly was 
also reported by others [11, 23–25]. Although signifi-
cantly lower in the obese Acro group with active disease 
compared to the CTL group, the trunk-to-leg fat ratio 
independently predicted BMD in both groups. We also 
previously reported positive independent effects of 
trunk-to-leg fat ratio upon BMD in overweight post-
menopausal women [26]. Kim et al. [27] found android 
fat to be positively related to BMD, but negatively 
related to trabecular bone score in postmenopausal 
women. Although adipokines were proposed to me-
diate the relationship between fat and bone [27], no 
significant associations between adipokines and BMD 
were found in multiple regression analysis in any of the 
study groups, after adjusting for age and BC. 
Nonetheless, the release of adipokines may account 
for the insulin resistance seen in acromegaly, despite 
a rather favourable BC [7]. Similarly to other studies, 
we report lower leptin concentrations that mirror the 
GH-regulated fat tissue depots [28, 29]. 
Insulin-sensitizing, anti-inflammatory, and anti-
atherogenic adiponectin is negatively correlated with 
visceral adiposity [30]. Similarly to previous data, higher 
adiponectin concentrations were encountered in Acro 
patients exhibiting lower visceral fat in our study [31, 
32]. On the other hand, patients suffering from acro-
megaly often associate CVD and insulin resistance, 
which are usually accompanied by hypoadiponectinae-
mia (32), which has also been described in this particular 
population [10]. Gurbulak et al. [31] hypothesized that 
adiponectin concentrations are elevated as a conse-
quence of GH-lowering therapies. Serum adiponectin 
did not vary significantly according to the presence 
of CVD, DM, or disease duration (newly diagnosed 
versus long-standing active acromegaly) in the cur-
rent research. Also, the negative relationship between 
adiponectin and total hip BMD was lost after adjusting 
for age and BC (the differences in serum adiponectin 
between eugonadal and hypogonadal were probably 
mediated by age and LM). The negative correlation 
between LM and adiponectin, also reported by oth-
ers (10), may reflect the link between muscle mass 
and the corresponding degree of insulin sensitivity. 
Recently, adiponectin was demonstrated to be merely 
a marker of insulin sensitivity, to have neutral effects 
upon non-fatal CV adverse events, but to paradoxi-
cally increase all-cause and CV mortality [33]. Hence, 
adiponectin merits further consideration regarding its 
potential as a CV risk marker in acromegaly. 
To our knowledge, only one study investigated the 
role of resistin in acromegaly-related metabolic disrup-
tion and reported similar serum resistin levels between 
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18 patients and corresponding controls [34]. Resistin 
is an adipocyte-derived hormone that “resists” insulin 
actions, therefore reflecting decreased insulin sensitiv-
ity [34]. We report significantly higher resistinaemia in 
Acro compared to CTL, despite lower visceral adipose 
depots. Resistin itself stimulates GH secretion in the 
pituitary [35], while GH increases resistin expression in 
animal studies [36]; this may explain the high resistin 
concentrations even in non-diabetic Acro patients com-
pared to the general population in our study, especially 
because serum resistin levels were not significantly 
influenced by the presence of CVD. Further research is 
needed to verify if GH increases insulin resistance via the 
direct induction of resistin expression in human subjects.
Acromegaly is the sole acquired disease accompa-
nied by an excess of serum a-Klotho [37], probably as 
a counterregulatory mechanism to the hyperactivity 
of the GH/IGF1 axis: while inhibiting the activation of 
the IGF1 receptor, it also opposes the GH effects upon 
calcium and phosphate metabolism [38, 39]. Although 
newly diagnosed Acro had a tendency to be associ-
ated with higher a-Klotho concentrations compared 
to the long-standing active Acro, we did not find any 
significant correlations between the GH/IGF1 axis 
and a-Klotho in our acromegaly patients. Moreover, 
a-Klotho was recently demonstrated in animal models 
to be a negative regulator of bone formation, indepen-
dently of FGF23 [12]. To our knowledge, our study is 
the first to investigate any relationship between the 
FGF23/a-Klotho axis and bone parameters in acro-
megaly. Although serum a-Klotho initially correlated 
with a high bone turnover, the relationship was lost in 
regression analysis. While it is true that our relatively 
small group of Acro patients was rather heterogenous 
with regards to disease duration and therapy, a-Klotho 
might be increased predominantly in particular sub-
groups of acromegaly — like the ones carrying the 
d3-GH receptor phenotype, and might be useful in 
determining patients at higher risk for recurrence de-
spite low post-surgical GH levels [40]. Nonetheless, the 
assays used to measure serum a-Klotho render poorly 
standardized results, and this may impede the general 
interpretation of literature data [37].  
Our study is limited by the small number of Acro 
patients enrolled — also impeding gender separate 
analysis, the cross-sectional design hindering the 
monitoring of patients and the heterogenous char-
acteristics of the study patients, especially regarding 
disease duration (newly diagnosed or long-standing). 
However, our study is among the first to investigate 
any given relationship between the FGF23/a-Klotho 
system and bone parameters, and also one of the first 
evaluating the impact of metabolic changes related to 
BC and adipokines on bone mass in acromegaly. The 
presence of a reference group is nonetheless one of the 
strengths of the study. 
Conclusions
Age and BC are the main BMD predictors in obese 
acromegalic patients with active disease, while bone 
turnover is independently related to IGF levels. Serum 
adipokines mirror the acromegaly-related metabolic 
changes, but do not appear to exert independent bone 
actions. Our study is among the first to report increased 
serum resistin in both diabetic and non-diabetic active 
Acro patients compared to the reference population, 
and the first to report the absence of a significant bone 
impact of the FGF23/ a-Klotho axis in patients with 
active acromegaly. The usefulness of a-Klotho in assess-
ing the activity of acromegaly on the long-term seems 
therefore rather limited.
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